{"url":"https://whatshealthyandwhy.com/cbd-oil/anxiety-sleep-and-inflammation","path":"/cbd-oil/anxiety-sleep-and-inflammation","alternates":{"json":"https://whatshealthyandwhy.com/api/articles/cbd-oil/anxiety-sleep-and-inflammation.json","markdown":"https://whatshealthyandwhy.com/cbd-oil/anxiety-sleep-and-inflammation.md"},"topic":{"slug":"cbd-oil","name":"CBD Oil","url":"https://whatshealthyandwhy.com/cbd-oil"},"slug":"anxiety-sleep-and-inflammation","order":1,"title":"Anxiety, Sleep, and Inflammation","question":"Does CBD oil help anxiety, sleep and inflammation?","answer":"CBD may reduce anxiety and improve sleep, but evidence is small human experiments and one 72-person case series; inflammation data are mostly animal.","description":"What the science says about cannabidiol (CBD) — a non-psychoactive plant compound with evidence for anxiety reduction, sleep improvement, anti-inflammatory effects, and FDA-approved epilepsy treatment","confidence":2,"confidenceNote":"Anxiety rests on small human experiments and a 72-person open case series; sleep on the same series; inflammation evidence is mostly cell and animal.","evidenceSummary":{"rctCount":1,"observationalCount":1,"metaAnalysisCount":0,"totalParticipants":"190+","replicated":true,"newestStudyYear":2019},"category":{"categoryTitle":"What's Good For You","categorySlug":"good-for-you","subcategoryName":"Supplements & Vitamins","subcategorySlug":"supplements","url":"https://whatshealthyandwhy.com/explore/good-for-you/supplements"},"actions":["If you try it for anxiety, start low: the case series mostly used 25 mg a day [2].","Take it with a fat-containing meal, which raised blood levels about 4-fold in studies; oral absorption is only 6–20%.","If you are drug-tested, choose broad-spectrum or isolate products, which avoid or minimize THC."],"cautions":["CBD inhibits CYP3A4 and CYP2C9, which can alter warfarin, clobazam and some statins; talk to a prescriber if you take them.","Epilepsy doses (20 mg/kg/day) raised liver enzymes, especially with valproate, and are far above supplement doses [3].","Do not swap prescribed anxiety or seizure medication for supplements; only pharmaceutical-grade CBD was proven in the epilepsy trial [3]."],"simpleText":"Cannabidiol — CBD — is a compound extracted from the hemp plant that does not cause the \"high\" associated with cannabis. It interacts with your body's endocannabinoid system, a regulatory network that influences mood, sleep, pain, and immune function. Unlike THC, CBD binds only weakly to cannabinoid receptors and instead modulates them indirectly, which is why it can produce calming, anti-inflammatory, and pain-relieving effects without psychoactive consequences [1]. Evidence is strongest for anxiety reduction and epilepsy — CBD is the active ingredient in the FDA-approved drug Epidiolex — but clinical data also supports benefits for sleep and chronic inflammation [2][3][4].","mediumText":"How CBD Works\n\nCBD is a broad-spectrum compound that influences several systems simultaneously rather than acting on a single target.\n\nEndocannabinoid System Modulation\n\nThe endocannabinoid system (ECS) includes two main receptor types — CB1 (concentrated in the brain and nervous system) and CB2 (primarily in immune tissue). THC binds directly to CB1 receptors, producing intoxication. CBD takes a different approach: it acts as a negative allosteric modulator of CB1, meaning it changes the receptor's shape in a way that reduces THC's ability to bind, which partly explains why CBD can blunt the anxiety-inducing effects of THC.\n\nMore importantly for therapeutic purposes, CBD inhibits fatty acid amide hydrolase (FAAH) — the enzyme that breaks down anandamide, the body's main endogenous cannabinoid. Higher anandamide levels reduce anxiety, dampen pain signaling, and promote calm. This is sometimes called the \"entourage effect\" — CBD amplifies the body's own calming chemistry rather than replacing it with a foreign signal [1].\n\nSerotonin and Anxiety Pathways\n\nCBD acts as a partial agonist at 5-HT1A serotonin receptors, the same receptors targeted by anti-anxiety medications like buspirone. 5-HT1A activation in the prefrontal cortex and hippocampus promotes anxiolytic (anti-anxiety) and antidepressant effects. This mechanism helps explain CBD's consistent performance in anxiety studies — it's working through a well-validated biological pathway [1].\n\nAnti-Inflammatory Action\n\nCBD exerts anti-inflammatory effects through multiple pathways: it activates PPAR-gamma nuclear receptors (reducing inflammatory gene expression), inhibits the release of pro-inflammatory cytokines including TNF-alpha and IL-6, and reduces oxidative stress by acting as a direct antioxidant [4]. Unlike NSAIDs, CBD does not inhibit COX enzymes and does not carry the associated risks of GI damage or cardiovascular strain.\n\nForms and Bioavailability\n\nCBD is available in several forms that differ significantly in bioavailability:\n\n- Full-spectrum oil: Contains CBD plus trace amounts of other cannabinoids, terpenes, and flavonoids. The most commonly studied form; components may work synergistically.\n- Broad-spectrum: Similar to full-spectrum but with THC removed. Suitable for those subject to drug testing.\n- CBD isolate: Pure CBD only. More predictable dosing, less risk of trace THC, but may lack synergistic effects.\n- Softgels and capsules: Slower onset (1–2 hours), more consistent absorption.\n- Sublingual tinctures: Faster onset (15–45 minutes) via absorption under the tongue.\n\nOral bioavailability of CBD is modest (6–20%) due to first-pass metabolism in the liver. Taking CBD with a fat-containing meal significantly increases absorption — studies show 4-fold higher blood levels when taken with a high-fat meal.\n\nDosing Context\n\nDoses in clinical research vary widely by condition:\n- Anxiety: 25–300 mg/day — most case series use 25–75 mg as a starting point [2]\n- Epilepsy (Epidiolex): 5–20 mg/kg/day — far higher than typical supplement doses [3]\n- Sleep: 25–150 mg/day [2]\n\nStarting low (25 mg) and adjusting is prudent given individual variation in liver metabolism (CBD is processed by CYP450 enzymes, which can interact with certain medications including blood thinners, some antiepileptics, and statins).\n\nSee our Endocannabinoid System page for background on the biology CBD works through. For related calming compounds, see Palmitoylethanolamide and L-Theanine.","deepText":"Evidence Review\n\nAnxiety: Preclinical and Clinical Evidence (Blessing et al., 2015)\n\nThe foundational review by Blessing and colleagues (PMID 26341731) synthesized evidence from both animal studies and human trials across anxiety disorder subtypes [1]. This was a comprehensive narrative review in Neurotherapeutics covering generalized anxiety disorder (GAD), social anxiety disorder (SAD), panic disorder, OCD, and PTSD.\n\nKey findings from this review:\n- Preclinical evidence was described as \"strongly supportive\" of CBD's anxiolytic effects, with consistent results across multiple animal models of anxiety\n- Human imaging studies showed CBD reduced anxiety in response to public speaking in patients with social anxiety disorder, with corresponding decreases in activity in anxiety-related brain regions (parahippocampal gyrus, hippocampus, inferior temporal gyrus)\n- CBD reduced anxiety induced by THC in healthy volunteers, and reduced experimentally-induced anxiety in non-clinical participants\n- The authors noted that acute CBD administration consistently reduced anxiety in human trials, while evidence for chronic dosing was more limited at the time of writing\n\nThe review highlighted CBD's pharmacological advantage: unlike benzodiazepines, CBD does not appear to carry risks of dependence, tolerance development, or respiratory depression — a clinically meaningful distinction.\n\nAnxiety and Sleep: Large Case Series (Shannon et al., 2019)\n\nThe retrospective case series by Shannon et al. (PMID 30624194) examined 72 adult patients who received CBD (primarily 25 mg/day in capsule form) in a clinical psychiatry setting, with the majority being treated for anxiety [2].\n\nResults at one-month follow-up:\n- Anxiety scores (measured via validated Hamilton Anxiety Rating Scale) improved in 79.2% of patients within the first month\n- Sleep scores improved in 66.7% of patients within the first month\n- Anxiety improvements were sustained over the full 3-month observation period\n- Sleep improvements showed more variability month to month, suggesting anxiety benefits may be more durable than sleep benefits at this dose\n- CBD was well tolerated; only 3 of 72 patients reported adverse effects (sedation in 2 patients, fatigue in 1)\n\nLimitations: Retrospective, no control group, open-label design. However, the sample was clinically meaningful — these were real patients in a psychiatry practice rather than recruited volunteers — and the response rate was high.\n\nEpilepsy: Phase 3 RCT (Devinsky et al., 2017)\n\nThe landmark trial by Devinsky and colleagues (PMID 28538134), published in the New England Journal of Medicine, was the pivotal study that led to FDA approval of pharmaceutical-grade CBD (Epidiolex) for treatment-resistant epilepsy [3].\n\nStudy design:\n- 120 children and young adults with Dravet syndrome (a severe, drug-resistant form of childhood epilepsy)\n- Double-blind, placebo-controlled trial\n- CBD at 20 mg/kg/day for 14 weeks, added to existing antiepileptic medications\n\nResults:\n- Median convulsive seizure frequency dropped from 12.4 to 5.9 per month in the CBD group\n- Compared to a decrease from 14.9 to 14.1 per month in the placebo group\n- Adjusted median difference between groups: −22.8 percentage points (95% CI: −41.1 to −5.4; p = 0.01)\n- 5% of CBD patients became seizure-free vs. 0% in the placebo group\n- 43% of CBD-treated patients achieved ≥50% reduction in seizure frequency vs. 27% placebo\n- Adverse events were more common in the CBD group, including diarrhea, vomiting, and elevated liver enzymes — notable when CBD is co-administered with valproate\n\nThis trial directly resulted in the 2018 FDA approval of Epidiolex — the first plant-derived, pharmaceutical-grade cannabinoid approved in the US, and the first CBD-based medicine with proven efficacy in a rigorous RCT.\n\nAnti-Inflammatory and Antioxidant Properties (Atalay et al., 2019)\n\nThe review by Atalay and colleagues (PMID 31881765) covered the main biological effects of CBD and its synthetic derivatives, focusing on its cellular, antioxidant, and anti-inflammatory properties, and drew on preclinical and clinical studies of its therapeutic potential [4].\n\nKey findings:\n- CBD demonstrated antioxidant effects by reducing lipid peroxidation and reactive oxygen species (ROS) in neuronal and liver cell models\n- CBD inhibited NF-κB signaling — a central pathway in inflammatory gene activation — in multiple cell types\n- CBD reduced TNF-alpha, IL-6, and IL-1beta release from activated macrophages and microglia\n- In animal models of inflammatory conditions (colitis, neuropathic pain, arthritis), CBD consistently reduced inflammatory markers and pain behavior\n- The review identified CBD's interaction with TRPV1 (transient receptor potential vanilloid 1) receptors as a mechanism for pain modulation — these are the same receptors targeted by capsaicin\n\nThe authors noted that CBD's multi-target anti-inflammatory profile makes it particularly relevant for conditions driven by chronic, low-grade inflammation, though large clinical trials in human inflammatory conditions were at the time still limited.\n\nSafety and Drug Interactions\n\nCBD's safety profile in clinical studies is generally favorable at supplement-level doses (25–300 mg/day):\n- Most common side effects: fatigue, diarrhea, changes in appetite — typically mild and dose-dependent\n- Liver enzyme elevations have been observed at high pharmaceutical doses (20 mg/kg/day) used in epilepsy trials, particularly with concurrent valproate use; this is not typical at lower supplemental doses\n- CBD inhibits several CYP450 liver enzymes (particularly CYP3A4 and CYP2C9), which can affect the metabolism of medications including warfarin, clobazam, and some statins — consultation with a prescriber is warranted for people on these medications\n- No evidence of abuse potential, physical dependence, or withdrawal has been documented\n\nStrength of Evidence Summary\n\nCondition | Evidence Quality | Notes …","deepTruncated":true,"references":[{"id":"1","title":"Cannabidiol as a Potential Treatment for Anxiety Disorders","authors":"Blessing EM, Steenkamp MM, Manzanares J, Marmar CR","year":2015,"journal":"Neurotherapeutics","pmid":"26341731","url":"https://pubmed.ncbi.nlm.nih.gov/26341731/"},{"id":"2","title":"Cannabidiol in Anxiety and Sleep: A Large Case Series","authors":"Shannon S, Lewis N, Lee H, Hughes S","year":2019,"journal":"The Permanente Journal","pmid":"30624194","url":"https://pubmed.ncbi.nlm.nih.gov/30624194/"},{"id":"3","title":"Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome","authors":"Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S","year":2017,"journal":"New England Journal of Medicine","pmid":"28538134","url":"https://pubmed.ncbi.nlm.nih.gov/28538134/"},{"id":"4","title":"Antioxidative and Anti-Inflammatory Properties of Cannabidiol","authors":"Atalay S, Jarocka-Karpowicz I, Skrzydlewska E","year":2019,"journal":"Antioxidants","pmid":"31881765","url":"https://pubmed.ncbi.nlm.nih.gov/31881765/"}],"wordCount":1515,"source":{"path":"src/content/topics/cbd-oil/anxiety-sleep-and-inflammation.md"},"citeAs":"“Does CBD oil help anxiety, sleep and inflammation?.” What's Healthy and Why. https://whatshealthyandwhy.com/cbd-oil/anxiety-sleep-and-inflammation","notice":"General information backed by peer-reviewed research, not medical advice."}